芦氟沙星及其代谢物MF 922的体外抗支原体活性。
In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.
作者信息
Furneri P M, Bisignano G, Cerniglia G, Nicoletti G, Cesana M, Tempera G
机构信息
Institute of Microbiology, University of Catania, Italy.
出版信息
Antimicrob Agents Chemother. 1994 Nov;38(11):2651-4. doi: 10.1128/AAC.38.11.2651.
Abstract
The in vitro activities of rufloxacin and its metabolite, MF 922, were compared with those of ofloxacin, ciprofloxacin, erythromycin, and minocycline against Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, and Ureaplasma urealyticum. Rufloxacin, MF 922, and ciprofloxacin shared similar activities against all mycoplasmas tested. (MICs for 90% of isolates tested [MIC90s], 0.5 to 4 micrograms/ml. Ofloxacin had the lowest MIC90s for U. urealyticum, M. fermentans, and M. hominis (MIC90s, 0.25 to 1 micrograms/ml) and erythromycin had the lowest MIC90 for M. pneumoniae (MIC90, 0.004 micrograms/ml).
摘要
将鲁氟沙星及其代谢产物MF 922的体外活性与氧氟沙星、环丙沙星、红霉素和米诺环素针对肺炎支原体、人型支原体、发酵支原体和解脲脲原体的活性进行了比较。鲁氟沙星、MF 922和环丙沙星对所有测试支原体具有相似的活性。（90%测试分离株的最低抑菌浓度[MIC90]，0.5至4微克/毫升。氧氟沙星对解脲脲原体、发酵支原体和人型支原体的MIC90最低（MIC90，0.25至1微克/毫升），而红霉素对肺炎支原体的MIC90最低（MIC90，0.004微克/毫升）。
相似文献
1
In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.芦氟沙星及其代谢物MF 922的体外抗支原体活性。
Antimicrob Agents Chemother. 1994 Nov;38(11):2651-4. doi: 10.1128/AAC.38.11.2651.
2
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.人型支原体、肺炎支原体和解脲脲原体对新型喹诺酮OPC 17116的敏感性
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
3
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).肺炎支原体、人型支原体和解脲脲原体对新型喹诺酮类药物曲伐沙星（CP-99,219）的敏感性
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
4
[In vitro activity of sparfloxacin against mycoplasmas].
Pathol Biol (Paris). 1992 May;40(5):450-4.
5
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.肺炎支原体、人型支原体和解脲脲原体对司帕沙星和PD 127391的体外敏感性
Antimicrob Agents Chemother. 1991 Jun;35(6):1181-5. doi: 10.1128/AAC.35.6.1181.
6
Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.人型支原体和解脲脲原体对两种新型喹诺酮类药物（司帕沙星和WIN 57273）的敏感性
Antimicrob Agents Chemother. 1991 Jul;35(7):1515-6. doi: 10.1128/AAC.35.7.1515.
7
Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis.左氧氟沙星、其他氟喹诺酮类、多西环素和红霉素对解脲脲原体和人型支原体的体外活性比较
J Antimicrob Chemother. 1999 Jun;43 Suppl C:33-6. doi: 10.1093/jac/43.suppl_3.33.
8
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.肺炎支原体、人型支原体和解脲脲原体对克林沙星、PD 131628、环丙沙星及对照药物的体外敏感性。
J Antimicrob Chemother. 1997 Aug;40(2):308-9. doi: 10.1093/jac/40.2.308.
9
In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas.吉米沙星（SB 265805；LB20304a）对人型支原体的体外活性
J Antimicrob Chemother. 2000 Mar;45(3):367-9. doi: 10.1093/jac/45.3.367.
10
In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
Chemotherapy. 1992;38(5):303-7. doi: 10.1159/000239018.
本文引用的文献
1
Breakpoint determination: rufloxacin.断点确定：鲁氟沙星。
Eur J Clin Microbiol Infect Dis. 1993 Jul;12(7):574-5. doi: 10.1007/BF01970973.
2
Potential improvements in therapeutic options for mycoplasmal respiratory infections.支原体呼吸道感染治疗选择的潜在改进。
Clin Infect Dis. 1993 Aug;17 Suppl 1:S202-7. doi: 10.1093/clinids/17.supplement_1.s202.
3
Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.每日一次芦氟沙星与每日两次氧氟沙星治疗复杂性膀胱炎和上尿路感染。意大利多中心泌尿道感染芦氟沙星研究组
Infection. 1993 Mar-Apr;21(2):106-11. doi: 10.1007/BF01710743.
4
In vitro antibiotic susceptibility testing of different strains of Mycoplasma fermentans isolated from a variety of sources.对从各种来源分离出的不同发酵支原体菌株进行体外抗生素敏感性测试。
Antimicrob Agents Chemother. 1993 Nov;37(11):2500-3. doi: 10.1128/AAC.37.11.2500.
5
Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis.每日一次芦氟沙星与每日三次阿莫西林治疗慢性支气管炎急性加重期门诊患者的双盲对照研究。
Antimicrob Agents Chemother. 1993 Nov;37(11):2298-306. doi: 10.1128/AAC.37.11.2298.
6
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.人型支原体、肺炎支原体和解脲脲原体对新型喹诺酮OPC 17116的敏感性
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
7
In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.芦氟沙星和环丙沙星对感染脆弱拟杆菌小鼠T细胞亚群及肿瘤坏死因子产生的体内效应
Antimicrob Agents Chemother. 1993 Aug;37(8):1711-2. doi: 10.1128/AAC.37.8.1711.
8
The penetration of rufloxacin into sites of potential infection in the respiratory tract.
J Antimicrob Chemother. 1993 Dec;32(6):861-6. doi: 10.1093/jac/32.6.861.
9
In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.芦氟沙星对单核细胞增生李斯特菌、嗜肺军团菌和沙眼衣原体的体外活性。
Chemotherapy. 1994 Mar-Apr;40(2):104-8. doi: 10.1159/000239180.
10
Antimycoplasmal activity of ofloxacin (DL-8280).氧氟沙星（DL-8280）的抗支原体活性。
Antimicrob Agents Chemother. 1983 Mar;23(3):509-11. doi: 10.1128/AAC.23.3.509.
Zotero 插件